Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Management is pivoting to a dual primary endpoint strategy for the ARCHER II Phase III trial in geographic atrophy (GA), adding a month 24 analysis to the existing month 15 target to maximize the probability of success and strengthen the potential label.
The decision to expand the GA program was driven by 'found power' from over-enrollment, high patient retention (less than 10% discontinuation), and masked event rates that are tracking precisely with internal projections. In Guillain-Barré Syndrome (GBS), the FORWARD study demonstrated that tanruprubart's rapid clinical benefit is reproducible in Western populations, with 100% of the first cohort showing meaningful improvement within four days. Management attributes the GBS program's success to the drug's ability to halt C1q-mediated neuroinflammation at the source, leading to unprecedented functional gains such as rapid weaning from mechanical ventilation.
The company is transitioning from a R&D-focused entity to a fully integrated biotech, supported by a new $200 million credit facility that extends the cash runway into 2028. Strategic positioning in GA focuses on vision preservation rather than just lesion growth, as management argues that protecting photoreceptors and the ellipsoid zone is the more clinically relevant metric for patient independence. Annexon is on track to submit the Biologics License Application (BLA) for tanruprubart in GBS to the FDA in the fourth quarter of 2024, incorporating data from the FORWARD study.
The month 15 primary endpoint for the ARCHER II GA trial remains the base case for success, with a readout expected from the Independent Data Monitoring Committee in Q4 2024. If the month 15 endpoint is met, the company will proceed to analyze two separate substudies with results expected in Q1 2027; otherwise, the trial will continue to the month 24 analysis in Q3 2027. The dual primary endpoint strategy requires a split of statistical alpha between the two time points, but management maintains that the study remains well-powered (over 90%) for both due to strong execution.
Ongoing engagement with the EMA via PRIME designation and the product development coordinator pilot is expected to expedite the regulatory path for vonaprument in Europe. The $200 million credit facility with Oxford Finance provides non-dilutive capital to support global commercialization efforts and diversifies the capital structure. The ARCHER II trial will remain masked through the month 24 analysis to preserve the integrity of the data, even if the month 15 look is positive.
Management explicitly noted that while RPE lesion growth is a historical focus in GA, they do not view it as the primary driver of vision protection, representing a strategic departure from current approved therapies. Mark Blumenkranz to the Board of Directors is intended to bolster internal ophthalmic expertise ahead of pivotal readouts. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
